New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2013
11:38 EDTUTHR, TIBX, PLCE, TIF, GESOptions with decreasing implied volatility: TIF TIBX GES PLCE UTHR
News For TIF;TIBX;GES;PLCE;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
11:12 EDTTIFCiti favors lululemon in retailing, says sell Penny and Kors
Citi analyst Paul Lejuez rolled out coverage of 20 companies in the Specialty Retailing and Department Stores space, recommending to investors that they sell J.C. Penney (JCP) and Michael Kors (KORS) shares and buy stock in lululemon (LULU). SELL J.C. PENNEY: Commenting on the "stormy sector" in general terms, Lejuez said he believes challenges to the retail industry are here to stay, but that there are still stand-outs on both the positive and negative side. Regarding J.C. Penney specifically, Lejuez told investors that the company's management is in a "tough spot," as they need to recover from a prior failed strategy but don't have the needed cash flow to invest and win back customers. The analyst think Penney will see some improvement in the top line, but that any increases in operating cash flow as a result of sales and margin improvement will be matched by increased capital expenditures, meaning that free cash flow will be "elusive for the foreseeable future. Lejuez started shares of J.C. Penney with a Sell rating and $7 price target. SELL KORS: Among the 20 stocks he started coverage on in the space, Michael Kors was the only other Sell rating the analyst issued. Lejuez believes the company has overdistributed its brand and though U.S. comparable sales have just started to decline he thinks this decline will last for the "foreseeable future." Lejuez, who contends that Europe and wholesale may be next to deteriorate, set a $38 price target on the stock. BUY LULULEMON: Among the ten Buy rating issued this morning, Lejuez said his most preferred stock in the bunch is yoga apparel maker lululemon. The analyst thinks the "athleisure" retailer has moved beyond its prior product and public relations missteps and that its international opportunities will provide the next leg of growth for the company. The analyst, who expects double-digit sales growth for the next several years for lululemon, set a $69 price target on its shares. His other Buy-rated names, in order of preference, include TJX (TJX), Tiffany (TIF), Urban Outfitters (URBN) and Ross Stores (ROST). PRICE ACTION: In morning trading, J.C. Penney fell 2.7% to $9.52, Michael Kors slipped 0.3% to $43.24 and lululemon shares rose 2.2% to $52.86.
10:01 EDTTIFOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:34 EDTTIFTiffany initiated with a Buy at Citi
Subscribe for More Information
07:29 EDTTIFJ.C. Penney initiated with a Sell, $7 target at Citi
Citi analyst Paul Lejuez started shares of J.C. Penney (JCP) with a Sell rating and $7 price target. The retailer closed yesterday down 6c to $9.73. The company's goals are aggressive while its free cash flow is "elusive," Lejuez told investors this morning in a research note. He initiated 19 other companies in the Specialty Retailing and Department Stores space. His Buy-rated names, in order of preference, include lululemon (LULU), TJX (TJX), Tiffany (TIF), Urban Outfitters (URBN) and Ross Stores (ROSS).
September 30, 2015
06:03 EDTUTHRUnited Therapeutics announces settlement of patent litigation with Sandoz
United Therapeutics announced that it has entered into a Settlement Agreement with Sandoz relating to ongoing litigation concerning certain patents relating to United Therapeutics' product, Remodulin Injection, and Sandoz's Abbreviated New Drug Application, or ANDA, seeking approval by the FDA to market a generic version of Remodulin. Under the Settlement Agreement, United Therapeutics granted to Sandoz a non-exclusive license to manufacture and commercialize the generic version of Remodulin described in its ANDA filing in the United States beginning on June 26, 2018, although Sandoz may be permitted to enter the market earlier under certain circumstances. The license included in the Settlement Agreement does not permit Sandoz the right to manufacture a generic version of any other United Therapeutics product, such as Tyvaso Inhalation Solution or Orenitram Extended-Release Tablets, nor does it grant any rights with respect to any technology associated with the Remodulin Implantable System being developed by the Company and Medtronic Inc., or the pre-filled semi-disposable pump system being developed by the Company and DEKA Research & Development Corp. The Settlement Agreement does not grant Sandoz any rights other than those required to launch Sandoz's generic version of Remodulin. In accordance with the Settlement Agreement, the parties will submit the Settlement Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
September 25, 2015
07:22 EDTUTHREuropean Society for Medical Oncology to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use